Design, synthesis, and biological evaluation of long-acting glucagon-like peptide-1 (GLP-1) conjugates modified with dual fatty acids and a proline-alanine-serine (PAS) polypeptide
Publication date: Available online 6 June 2025 Source: Bioorganic & Medicinal Chemistry Author(s): Chengcheng Wang, Jinhua Zhang, Yuanzhen Dong, Jun Xu, Jianguang Lu, Chunyong Ding, Zhengyan Cai, Jun Feng
Ozempic makes you twice as likely to develop this debilitating condition — what that really means for your risk
A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.
Ozempic has ‘very rare’ sight loss side effect, EU drugs regulator finds
Patients taking weight-loss and diabetes drugs Wegovy and Ozempic have an increased risk of developing a rare eye condition that could lead to loss of vision, a European Medicines Agency (EMA) committee announced Friday. The EMA’s drug safety committee (PRAC) launched a review of medicines containing semaglutide — a GLP-1 agonist and the active ingredient […]
STAT+: Pharmalittle: We’re reading about GLP-1 drugs and eye disease, European pharma reforms, and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, but we expect to manicure the Pharmalot grounds, promenade extensively with the official mascots, and attend some outdoor festivities. […]
STAT+: A kidney disease showdown, and eye risk linked to GLP-1s
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, happy Friday! Let’s get into the news. Otsuka tops Vera Therapeutics in kidney disease study showdown From STAT’s Adam Feuerstein: Another example of why biotech is a tough business. Continue to STAT+ […]
Diabetes patients who use GLP-1s may have a higher risk of serious eye disease: study
In the study, diabetes patients who took GLP-1s were twice as likely to develop neovascular age-related macular degeneration (nAMD) than those without GLP-1 exposure.
Novo’s Ozempic Linked to Rare Cases Of Serious Eye Disorder, EU Regulator Says
Novo Nordisk’s popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision loss, the European… Reuters Health Information
‘Ozempic Teeth’ May Cause Tooth Decay, Other Dental Health Effects
People using GLP-1 drugs are reporting an unusual side effect impacting dental health that some are calling “Ozempic teeth.” Jacob Wackerhausen/Getty Images People using GLP-1 drugs like Ozempic are reporting what they call “Ozempic teeth.” The unusual side effect refers to the dental health impacts of GLP-1 drugs, including tooth decay, sensitivity, and tooth loss. […]
Ozempic users report surprising cravings for certain smells: Here’s what to know
While Ozempic and other weight-loss drugs have been shown to have myriad benefits, they can also present some unwelcome effects, primarily nausea, vomiting and other gastrointestinal symptoms. Some are also reporting changes in their sense of smell — sometimes referred to as “Ozempic smell” — as one of the lesser-known side effects of GLP-1 medications. […]
Semaglutide Linked to Age-Related Macular Degeneration Risk
(MedPage Today) — Older adults taking GLP-1 receptor agonists, primarily semaglutide (Rybelsus, Ozempic, Wegovy), had a small uptick in their risk of developing neovascular age-related macular degeneration (nAMD), according to a retrospective…